Business Context and Reporting Period
Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 8-K (Current Report)
Date: May 21, 2026
Context: The Company is an emerging growth company focused on oncology. This filing discloses positive Phase 2 clinical trial results for its lead candidate, silevertinib, in frontline non-small cell lung cancer (NSCLC) patients with EGFR non-classical mutations (NCMs).
Key Financial Metrics
This Form 8-K is a disclosure of clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Highlights
The primary material event is the announcement of updated data from the silevertinib Phase 2 trial (data cutoff: April 11, 2026). Key clinical metrics include:
- Study Population: 43 frontline NSCLC patients with EGFR-NCMs (including PACC mutations); 19 had brain metastases.
- Durability: Preliminary median progression-free survival (PFS) is 15.2 months (95% CI: 10.8, NE). Median duration of response (DOR) was not reached.
- Response Rates: Overall Response Rate (ORR) by RECIST 1.1 is 60%; Disease Control Rate (DCR) is 91%.
- CNS Activity: CNS ORR (RANO-BM) remains at 86%. No patients developed de novo brain metastases.
- Safety: No new safety signals. Treatment-related adverse events > Grade 3 reduced to 28% following dose reduction. Data supports 150 mg QD for pivotal development.
Guidance, Outlook, and Risks
Outlook: Management indicated that safety and efficacy data support advancing silevertinib to pivotal development at a 150 mg daily dose. The study remains ongoing with 53% of patients (23 of 43) still on therapy.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, competitive landscape, and the potential for actual results to differ materially from expectations. The Company references risks detailed in its 2025 Form 10-K.
Investor Verification Checklist
- Verify the specific definitions of "non-classical mutations" and the breakdown of the 25 unique EGFR-NCMs observed.
- Confirm the timeline for initiating the pivotal Phase 3 trial based on the 150 mg dose recommendation.
- Review the Company's cash runway and capital requirements in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Assess the competitive landscape for EGFR-NCM therapies to evaluate market opportunity.
- Monitor subsequent filings for any updates on the 23 patients remaining on therapy and long-term safety data.